Stock Detail
MEDICIS PHARMACEUTICAL CORPORATION
Consumer Non-Durables
MRX @ Yahoo Finance | MRX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $32.62 | $33.50 | $-0.13 | -0.40% | 0.32 | $32.75 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $32.63 | $32.53 | 2.64M | 2B | 1.12M | 23.57 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 33.85 | 33.23 | 32.88 | 32.26 | 31.91 |
Stock Profile
Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, focuses on the development and marketing of products for the treatment of dermatological, aesthetic, and podiatric conditions in the United States and Canada. It offers a range of products addressing various conditions, including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis, and cosmesis. The company's product portfolio comprises DYNACIN, an oral adjunctive treatment for moderate to severe acne; LOPROX, a topical treatment for certain fungal and yeast infections; OMNICEF, a patented oral cephalosporin for skin and skin-structure infections; PLEXION, topical treatments for rosacea and acne-related conditions; RESTYLANE, an injectable gel for treatment of fine lines and wrinkles, shaping facial contours, and correcting deep facial folds; TRIAZ, topical patented gel, cleanser, and patent-pending pad treatments for acne; and VANOS, topical corticosteroid for the treatment of plaque type psoriasis in adult patients. It also offers PERLANETM and RESTYLANE FINE LINES, which are injectable, transparent, and nonanimal-stabilized-hyaluronic acid gels for the treatment of fine lines and wrinkles, and correcting deep facial folds. The company's nondermatological product line includes AMMONUL, as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle; and BUPHENYL, an adjunctive maintenance therapy for urea cycle disorders. Its customers include wholesale pharmaceutical distributors and other drug chains. The company has a strategic alliance with aaiPharma, Inc. Medicis Pharmaceutical was founded in 1987 and is headquartered in Scottsdale, Arizona.